NASDAQ:PRPO

Precipio Stock Forecast, Price & News

$2.45

0.00 (0.00 %)

(As of 01/21/2021 12:00 AM ET)

Add

Compare

Today's Range

$2.34

Now: $2.45▼

$2.55

50-Day Range

$2.01

MA: $2.23▼

$2.45

52-Week Range

$0.55

Now: $2.45▼

$8.00

Volume858,152 shs

Average Volume880,624 shs

Market Capitalization$42.21 million

P/E RatioN/A

Dividend YieldN/A

Beta2.9

Precipio, Inc., a cancer diagnostics company, provides diagnostic products and services in the United States oncology market. Its product consists of clinical diagnostic services. The company's clinical diagnostic services focus on the diagnosis of different hematopoietic or blood-related cancers to oncologists. Its cytogenetics media IV-Cell enables laboratories to arrive at more accurate results; and HemeScreen panel enables hospitals and laboratories to run an important genetic mutation test. It serves oncologists, hospitals, reference laboratories, and pharma and biotech companies. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment, such as the Yale School of Medicine and Harvard's Dana-Farber Cancer Institute. The company is based in New Haven, Connecticut.

MarketRank^™

Overall MarketRank^™

1.05 out of 5 stars

Medical Sector

945th out of 1,926 stocks

Analytical Instruments Industry

18th out of 29 stocks

1.5 Analyst's Opinion

Consensus Rating
Precipio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $2.00, Precipio has a forecasted downside of 18.4% from its current price of $2.45.
Amount of Analyst Coverage
Precipio has received no research coverage in the past 90 days.

2.9 Community Rank

Outperform Votes
Precipio has received 269 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Precipio has received 194 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Precipio has received 58.10% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Precipio and other stocks. Vote “Outperform” if you believe PRPO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PRPO will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Precipio does not currently pay a dividend.
Dividend Growth
Precipio does not have a long track record of dividend growth.

0.8 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Precipio insiders have bought more of their company's stock than they have sold. Specifically, they have bought $2,973.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 9.70% of the stock of Precipio is held by insiders.
Percentage Held by Institutions
Only 3.22% of the stock of Precipio is held by institutions.

0.0 Earnings and Valuation

Price to Book Value per Share Ratio
Precipio has a P/B Ratio of 1.48. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Analytical instruments

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:PRPO

Previous Symbol

CUSIPN/A

CIK1043961

Webwww.precipiodx.com

Phone(203) 787-7888

Employees50

Debt

Debt-to-Equity Ratio0.04

Current Ratio0.89

Quick Ratio0.83

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$3.13 million

Price / Sales13.48

Cash FlowN/A

Price / Cash FlowN/A

Book Value$1.65 per share

Price / Book1.48

Profitability

EPS (Most Recent Fiscal Year)N/A

Net Income$-13,240,000.00

Net Margins-258.88%

Return on Equity-98.29%

Return on Assets-64.03%

Miscellaneous

Outstanding Shares17,227,000

Market Cap$42.21 million

Next Earnings Date2/12/2021 (Estimated)

OptionableNot Optionable

$2.45

0.00 (0.00 %)

(As of 01/21/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive PRPO News and Ratings via Email

Sign-up to receive the latest news and ratings for PRPO and its competitors with MarketBeat's FREE daily newsletter.

Precipio (NASDAQ:PRPO) Frequently Asked Questions

How has Precipio's stock price been impacted by Coronavirus (COVID-19)?

Precipio's stock was trading at $1.17 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, PRPO stock has increased by 109.4% and is now trading at $2.45.
View which stocks have been most impacted by COVID-19.

Is Precipio a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Precipio in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Precipio stock.
View analyst ratings for Precipio or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Precipio?

Wall Street analysts have given Precipio a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Precipio wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Precipio's CEO?

1,448 employees have rated Precipio CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among Precipio's employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is Precipio's next earnings date?

Precipio is scheduled to release its next quarterly earnings announcement on Friday, February 12th 2021.
View our earnings forecast for Precipio.

How were Precipio's earnings last quarter?

Precipio, Inc. (NASDAQ:PRPO) issued its quarterly earnings data on Friday, November, 13th. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter. The biotechnology company earned $1.63 million during the quarter. Precipio had a negative net margin of 258.88% and a negative return on equity of 98.29%.
View Precipio's earnings history.

When did Precipio's stock split? How did Precipio's stock split work?

Precipio's stock reverse split on the morning of Tuesday, June 6th 2017. The 1-30 reverse split was announced on Thursday, May 25th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 5th 2017. An investor that had 100 shares of Precipio stock prior to the reverse split would have 3 shares after the split.

What price target have analysts set for PRPO?

1 analysts have issued twelve-month price targets for Precipio's shares. Their forecasts range from $2.00 to $2.00. On average, they anticipate Precipio's share price to reach $2.00 in the next twelve months. This suggests that the stock has a possible downside of 18.4%.
View analysts' price targets for Precipio or view Wall Street analyst' top-rated stocks.

Who are some of Precipio's key competitors?

Some companies that are related to Precipio include Harvard Bioscience (HBIO), Astrotech (ASTC), HTG Molecular Diagnostics (HTGM), Scientific Industries (SCND), Pressure BioSciences (PBIO), BioForce Nanosciences (BFNH), Arrayit (ARYC), DiaSys (DYXC), HORIBA (HRIBF), Orthometrix (OMRX) and PositiveID (PSID).
View all of PRPO's competitors.

What other stocks do shareholders of Precipio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Precipio investors own include Biocept (BIOC), Heat Biologics (HTBX), Portola Pharmaceuticals (PTLA), iBio (IBIO), Inovio Pharmaceuticals (INO), T2 Biosystems (TTOO), VBI Vaccines (VBIV), Co-Diagnostics (CODX), Inpixon (INPX) and Jaguar Health (JAGX).

Who are Precipio's key executives?

Precipio's management team includes the following people:

Mr. Ilan Danieli, Founder, Pres, CEO & Director (Age 48, Pay $263.56k)
Mr. Carl R. Iberger, CFO & Sec. (Age 67, Pay $210.67k)
Mr. Ahmed Zaki Sabet, Chief Operating Officer (Age 33, Pay $173.76k)
Mr. Stephen R. Miller, Chief Commercial Officer (Age 54, Pay $252.21k)
Ms. Miri Chiko-Radomski, Gen. Counsel
Mr. Douglas Sites, VP of Sales
Mr. Ayman Mohamed M.D., Sr. VP of R&D and Laboratory Operations (Age 34)
Mr. Ori Karev, Chief Strategy Officer

What is Precipio's stock symbol?

Precipio trades on the NASDAQ under the ticker symbol "PRPO."

How do I buy shares of Precipio?

Shares of PRPO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Precipio's stock price today?

One share of PRPO stock can currently be purchased for approximately $2.45.

How big of a company is Precipio?

Precipio has a market capitalization of $42.21 million and generates $3.13 million in revenue each year. Precipio employs 50 workers across the globe.

What is Precipio's official website?

The official website for Precipio is www.precipiodx.com.

How can I contact Precipio?

Precipio's mailing address is 4 Science Park, New Haven CT, 06511. The biotechnology company can be reached via phone at (203) 787-7888 or via email at [email protected]

This page was last updated on 1/22/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here